Q2 2023 · 13F-HR
Paradigm Biocapital Advisors LPholdings as filed
Filed 2023-08-14 · accession 0001855655-23-000008
$1.29B
Reported value
30
Positions
2023-06-30
Period end
Holdings as filed
| CUSIP | Ticker | Issuer | Value | % port. | Shares | Class | Voting |
|---|---|---|---|---|---|---|---|
| 52490G102 | LEGN | LEGEND BIOTECH CORP | $124.6M | 9.63% | 1,805,717 | Common | SOLE |
| 45337C102 | INCY | INCYTE CORP | $86.0M | 6.65% | 1,381,711 | Common | SOLE |
| 45258D105 | IMCR | IMMUNOCORE HLDGS PLC | $76.2M | 5.88% | 1,270,124 | Common | SOLE |
| 03940C100 | ACLXGBX | ARCELLX INC | $74.2M | 5.73% | 2,347,000 | Common | SOLE |
| 48576A100 | — | KARUNA THERAPEUTICS INC | $61.5M | 4.75% | 283,605 | Common | SOLE |
| 15678U128 | CERE1EUR | CEREVEL THERAPEUTICS HLDNG I | $59.4M | 4.59% | 1,868,946 | Common | SOLE |
| 04016X101 | ARGX | ARGENX SE | $58.5M | 4.52% | 150,000 | PUT | SOLE |
| 92790C104 | VRDN | VIRIDIAN THERAPEUTICS INC | $57.5M | 4.44% | 2,415,256 | Common | SOLE |
| 04016X101 | ARGX | ARGENX SE | $55.4M | 4.28% | 142,259 | Common | SOLE |
| 91307C102 | UTHR | UNITED THERAPEUTICS CORP DEL | $52.6M | 4.07% | 238,388 | Common | SOLE |
| 60468T105 | MRTXEUR | MIRATI THERAPEUTICS INC | $52.2M | 4.03% | 1,443,762 | Common | SOLE |
| 87164F105 | SNDX | SYNDAX PHARMACEUTICALS INC | $50.7M | 3.92% | 2,424,132 | Common | SOLE |
| 088786108 | BCYC | BICYCLE THERAPEUTICS PLC | $50.7M | 3.92% | 1,985,430 | Common | SOLE |
| 670703107 | NUVL | NUVALENT INC | $47.3M | 3.65% | 1,120,465 | Common | SOLE |
| 07725L102 | ONC | BEIGENE LTD | $38.5M | 2.98% | 216,093 | Common | SOLE |
| 98420N105 | XENE | XENON PHARMACEUTICALS INC | $38.1M | 2.94% | 989,327 | Common | SOLE |
| 68062P106 | OLMA | OLEMA PHARMACEUTICALS INC | $33.7M | 2.60% | 3,731,046 | Common | SOLE |
| 02290A102 | — | AMBRX BIOPHARMA INC | $27.2M | 2.10% | 1,650,499 | Common | SOLE |
| 22663K107 | CRNX | CRINETICS PHARMACEUTICALS IN | $25.1M | 1.94% | 1,395,002 | Common | SOLE |
| 02083G100 | NVLSEUR | ALPINE IMMUNE SCIENCES INC | $24.9M | 1.93% | 2,423,961 | Common | SOLE |
| 92764N102 | VIR | VIR BIOTECHNOLOGY INC | $24.9M | 1.92% | 1,014,239 | Common | SOLE |
| 98887Q104 | ZLAB | ZAI LAB LTD | $24.0M | 1.85% | 865,297 | Common | SOLE |
| N44445109 | IMTX | IMMATICS N.V | $22.9M | 1.77% | 1,984,813 | Common | SOLE |
| 05280R100 | AUTL | AUTOLUS THERAPEUTICS PLC | $21.9M | 1.70% | 9,217,150 | Common | SOLE |
| 929033108 | — | VOR BIOPHARMA INC | $20.0M | 1.54% | 6,461,467 | Common | SOLE |
| 558868105 | MDGL | MADRIGAL PHARMACEUTICALS INC | $19.6M | 1.52% | 85,000 | Common | SOLE |
| 925050106 | VRNA | VERONA PHARMA PLC | $18.9M | 1.46% | 893,861 | Common | SOLE |
| 61559X104 | MLTX | MOONLAKE IMMUNOTHERAPEUTICS | $18.9M | 1.46% | 369,615 | Common | SOLE |
| 88369M101 | — | THESEUS PHARMACEUTICALS INC | $18.2M | 1.41% | 1,950,327 | Common | SOLE |
| 50127T109 | KURA | KURA ONCOLOGY INC | $10.6M | 0.82% | 1,004,908 | Common | SOLE |
Source: SEC EDGAR · raw 13F holdings as filed. The Class column shows the option type when reported (Put/Call) or Common when the issuer's equity is held directly. 13F discloses long positions only.